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The treatment of patients with non-
Hodgkin’s lymphoma (NHL) is often the treat-
ment of elderly patients, as most patients are
older than 65 years at diagnosis. These elderly
patients present particular therapeutic chal-
lenges, because they may be more frail and at
greater risk of treatment-related toxicity, espe-
cially anthracycline-related cardiotoxicity, than
younger patients. The following two case
studies illustrate the challenges and thera-
peutic decision-making in managing elderly
patients with an aggressive and an indolent
form of lymphoma. 
Case 1 - Elderly woman withexisting cardiopathy 
History 
This woman was aged 79 years at presenta-
tion. She had a history of congestive car-
diopathy and myocardial ischemia, and had
undergone angioplasty 10 years earlier. Her re-
cent history included a hospital admission due
to abdominal pain. Initial patient “work-up” re-
vealed the presence of a solid hypoechogenic
abdominal mass, of around 10 cm, on abdom-
inal ultrasound. The patient was referred for
diagnostic procedures. 
Diagnosis and staging
• Clinical examination showed no systemic
signs or symptoms. 
• Laboratory investigations showed that com-
plete blood count, hemoglobin, albumin, he-
patorenal function, lactate dehydrogenase
(LDH), beta-2 microglobulin, and serum
electrophoresis were all within the normal
range.
• A computed tomography (CT) scan revealed
a dishomogeneous mass with rounded mar-
gins and a longest transverse diameter of 10
cm in the left flank region of the abdomen.
The mass included the superior mesenteric
artery, with no signs of compression. 
• Diagnostic laparoscopy was performed, and
a diagnosis of diffuse large B-cell lymphoma
(DLBCL: CD20+, CD10–, CD5–) was made.
The proliferation index, measured with
MIB-1 staining, was 80%.1
• Bone marrow biopsy showed no evidence of
lymphoma. 
• A 2-dimensional echocardiogram showed
signs of pre-existing ischemic cardiopathy
with moderate reduction of ventricular func-
tion and moderate valvular incontinence.
The left ventricular ejection fraction (LVEF)
was 35%. 
Final diagnosis 
The final diagnosis was therefore: DLBCL,
stage IA, bulky, subdiaphragmatic unresectable
disease, with an International Prognostic
Index (IPI) of 1, due to advanced age. 
Assessment for treatment 
According to data from epidemiological
studies, the median age of patients with
DLBCL at the time of diagnosis is around 65
years, and one fifth of them are, like the re-
ported case, within the age range of 75-80
years. Older patients with DLBCL generally
show a relatively short life expectancy: overall
median survival is around 12 months (range 2-
23) and 15% die within 3 months of diagnosis.2
However, these poor results may vary when
analysis is limited to patients who are initially
approached with curative intent. In such cases,
median overall survival increases to 36
months, compared with 6 months for patients
in this age range who are treated with only pal-
liative intent. The main issue in elderly DLBCL
patients is then to properly decide who is suit-
able for a full course of therapy.
The rituximab, cyclophosphamide, doxoru-
bicin, vincristine, and prednisone (R-CHOP)-
21 regimen appears to be a good option for eld-
erly patients with aggressive lymphoma. The
addition of rituximab to the standard CHOP
regimen has been shown to increase its effi-
cacy, in both young and elderly patients.3-6 In
addition, although CHOP-14 was shown to be
more effective than CHOP-21,7,8 interim
analyses of comparisons of R-CHOP-21 and R-
CHOP-14 have shown no significant differ-
ences in efficacy between these two regi-
mens.9,10 As the R-CHOP-14 regimen is more
dose intense, and may therefore be associated
with more toxicities, the R-CHOP-21 regimen
may be preferable in elderly patients. 
As this patient had existing cardiopathy and
a low LVEF, she would be at increased risk of
cardiotoxicity during anthracycline treatment.
However, her disease, due to the limited stage
and favorable prognostic features, may be
cured, with a high chance of success, if the
standard approach was adopted. She would
therefore probably benefit from the use of a
standard regimen adapted to her concomitant
disorders. Among the different strategies
adaptable for this patient, there is the possi-
bility of reducing the drug doses, using treat-
ment regimens specifically designed for eld-
erly patients, or using different formulations
of the active drugs, allowing reduced toxicity.
For this last strategy, the availability of the
non-pegylated liposomal doxorubicin (NPLD)
formulation makes it feasible to substitute
conventional doxorubicin in the R-CHOP reg-
imen, defining a different, potentially more
tolerable, therapy, namely the R-COMP reg-
imen. A prospective study in patients with
lymphoma who were at risk of cardiotoxicity,
and who received R-COMP therapy, showed a
promising complete response rate of 76%, and
only one patient developed an acute grade III
cardiotoxicity.11 In addition, a prospective,
non-randomized study of R-COMP in elderly
patients with DLBCL showed no changes in
LVEF, and no cardiotoxic effects of this reg-
imen during treatment.12 This patient was
therefore treated with R-COMP (NPLD dose of
50 mg/m2) for four cycles, followed by involved-
field radiation therapy. She also received pro-
phylactic granulocyte colony-stimulating factor
and erythropoietin, and prednisone was low-
ered to half dose in cycles 3 and 4 in order to
reduce steroid-related toxicity. 
Treatment outcomes and follow-up 
At the end of treatment, the patient showed
no change in LVEF, which remained at 35%, and
was assessed as having an unconfirmed com-
plete response. She was diagnosed with a pul-
monary embolism at the end of chemotherapy,
which resolved during treatment with low-mo-
lecular-weight heparin. Her LVEF has since de-
teriorated to 30%. This patient remains in com-
plete remission after 7 years.
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Case 2 - Elderly man with a history of cardiovascular disease 
History 
This 77-year-old man was admitted to hos-
pital due to abdominal pain and the pres-
ence of a palpable mass. The patient had a
history of myocardial infarction 2 years be-
fore admission, which had been treated with
coronary stenting. He had persistent arterial
hypertension. 
Diagnosis and staging 
• The patient underwent laparoscopic biopsy,
and the histologic diagnosis was grade 2 fol-
licular lymphoma (FL). 
• CT and positron emission tomography
scans confirmed the presence of an abdom-
inal mesenteric mass with pathologic
adenopathies in the mediastinum and neck. 
• Laboratory tests showed normal values for
white blood count, hemoglobin, platelets,
and erythrocyte sedimentation rate, but ele-
vated LDH and beta-2 microglobulin. 
• Bone marrow biopsy revealed several
perivascular and paratrabecular lymphoid
aggregates, comprising B-lymphocytes ex-
pressing CD20 and CD10. 
• A 2-dimensional echocardiogram showed
normal cardiac function, with an LVEF of
65%, and the patient had a normal stress
electrocardiogram. 
Final diagnosis 
The final diagnosis was therefore: grade 2
FL, stage IVA. The patient’s follicular lym-
phoma IPI (FLIPI) score was 4 (due to ad-
vanced age, stage, elevated LDH, and number
of nodal sites).13 His FLIPI2 score was also 4
(due to advanced age, elevated beta-2 mi-
croglobulin, bone marrow involvement, and
longest diameter of the largest involved node
>6 cm).14
Assessment for treatment 
As this patient was generally healthy, he
could be expected to have a life expectancy of
around 10-15 years if he did not have lym-
phoma.15 Older data indicate that, for such a
patient with a poor prognosis, the 5-year
overall survival rate would only be expected to
be around 50%.13 However, these data were
produced before the availability of rituximab,
and the use of this chemotherapy combined
with monoclonal antibody has changed out-
comes for patients with FL. A more realistic 5-
year overall survival rate with chemo-im-
munotherapy would be 70%. However, if the
patient has an indolent lymphoma and is in his
eighth decade, he may experience a signifi-
cant reduction in life expectancy if not properly
cured of his disease.
It is not currently clear what the optimal
chemotherapy is for FL. Some study data
were obtained before the widespread use of
rituximab, and others before the availability
of the REAL classification of lymphomas,16
when FL was less strictly defined and was in-
cluded among other indolent lymphomas.
Based on the most recent data, a large pro-
portion of patients are treated with R-CHOP,
although rituximab, cyclophosphamide, vin-
cristine, and prednisone (R-CVP) and flu-
darabine-based regimens such as rituximab,
fludarabine, and mitoxantrone (R-FM) are
also used. The FOLL05 study (NCT00774826)
is currently underway to investigate the op-
timal therapy for FL, comparing R-CHOP, R-
CVP, and R-FM in patients with stage II-IV
newly diagnosed FL. This randomized study
will provide a definite answer on which ini-
tial treatment should be proposed for pa-
tients with FL, and whether anthracyclines
are also needed in this lymphoma subtype;
the final results should be available by mid-
2011. In addition, bendamustine plus ritux-
imab has produced promising results in fol-
licular lymphoma, with a better tolerability
profile compared with R-CHOP.17
Treatment outcomes and follow-up 
In this case, the patient received R-COMP
therapy, on the assumption that he was at high
risk of cardiotoxicity if conventional doxoru-
bicin were to be used. He received six cycles of
R-COMP, with 75% of the usual dose of NPLD
during cycle 1, followed by two further doses of
rituximab (similar to the regimen found to be
effective in elderly patients with NHL).5 At the
end of treatment the patient achieved a com-
plete remission, and after 30 months of follow-
up remains in complete remission with an ex-
cellent performance status and a conserved
quality of life. 
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